Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Is Cannabis Considered a Separate Dystonia Therapy in Clinics? 

Posted
Updated
ByMy Patient Advice
Author: Dr. Clarissa Morton, PharmD

In the UK, cannabis is not considered a separate or routine therapy for dystonia. 
While some clinics prescribe cannabis-based products privately for symptom relief, NHS and NICE guidance do not recognise it as a standard or licensed treatment for dystonia. 

Does cancer-related care qualify for medical cannabis?

How Clinics View Cannabis in Dystonia Care 

Dystonia management typically includes botulinum toxin injections, oral medications such as anticholinergics or benzodiazepines, and physiotherapy. These are established, evidence-based options supported by NICE and NHS frameworks. 

Medical cannabis, by contrast, is viewed as an experimental or adjunct therapy. It may be offered in private clinics when other treatments have not worked, but it remains outside standard NHS care. 

What The Evidence Suggests 

A 2023 study in Frontiers in Neurology followed 23 dystonia patients prescribed medical cannabis. They reported 63% symptom reduction and improvements in pain, spasms, and quality of life. 

However, researchers noted that the study was small and observational, meaning it does not prove cannabis is an effective treatment. 

Further reviews, such as the 2025 analysis of cannabinoids in movement disorders (PMC11839665), found that while some patients experienced benefit, clinical trials are still lacking. 

The Regulatory and Clinical Context 

According to NHS guidance and NICE Guidance NG144, cannabis-based medicinal products can only be prescribed for a few severe conditions: 

  • Multiple sclerosis-related spasticity 
  • Severe epilepsy 
  • Chemotherapy-induced nausea 

Dystonia is not included among these approved uses. The MHRA classifies cannabis for dystonia as unlicensed, meaning it can only be prescribed as a “special” medicine by a qualified specialist doctor. 

Key Clinical Insights 

  • Cannabis is not a recognised standalone therapy for dystonia in UK clinics. 
  • It may be considered only after standard options fail. 
  • Evidence remains limited, with no large randomised controlled trials. 
  • NHS and NICE do not currently endorse it for dystonia management. 

Safe Next Steps 

Providers like AlleviMed can help patients understand when and how medical cannabis may be considered under UK regulations. 

Anyone exploring this option should speak with a neurologist or specialist prescriber to ensure treatment decisions are safe, evidence-based, and legally compliant. 

Takeaway 

Cannabis is not considered a separate or standard dystonia therapy in UK clinics. While early evidence hints at possible benefits, it remains an unlicensed, specialist-prescribed option that should only be used when conventional treatments have failed and under professional medical supervision. 

Dr. Clarissa Morton, PharmD
Author

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Categories